NL-OMON43575已完成不适用
Immune repertoire changes in Alzheimer*s disease: a pilot study - Immune repertoire changes in Alzheimer*s disease: a pilot study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Group 1: Alzheimer*s Disease
- •- Diagnosis of AD according to the NIA-AA criteria (McKhann 2011)
- •- MMSE score of 18-*27
- •- Have abnormal CSF *-amyloid concentration and/or *-amyloid PET evidence for AD pathology
- •- *50 years old;Group 2: Subjective Cognitive Decline
- •- No objective memory loss with normal results on neuropsychological tests and no other explanation for memory complaints.
- •- MMSE score of 27-30
- •- Normal CSF *-amyloid concentrations or *-amyloid PET imaging
- •- *50 years old;Group 3: Young healthy controls
- •- No memory complaints
- •- MMSE score of 27-30
- •- 18-30 years of age
排除标准
- •- History of concussion or other acute head trauma in the past six months
- •- Currently engaging in activity (e.g. rugby) likely to induce repetitive head trauma
- •- Stroke or other ischemic incident within the past six months
- •- Current or past diagnosis of autoimmune disease
- •- Current or past diagnosis of immunosuppressive disorder
- •- Ongoing or past (within the last 3 months) treatment with any immunosuppressive drug (e.g. prednisone)
- •- Ongoing or past (within the last 3 months) treatment with drugs (e.g. Anakinra) that suppress the interleukin-1, interleukin-6, or TNF-* response EXCEPT NSAIDs.
- •- Current or previous (within the past year) treatment for malignancy
- •- Current or previous diagnosis of hematological malignancy
- •- Recent transfusion or treatment with blood products such as IVIG
- •- Diagnosis of HIV, HBV, or HCV
- •- Judged not to be of sound mind and judgement;Additional exclusion criteria per research group:
- •- Any current medical or neurological condition other than AD that could explain the patient*s dementia
- •- Diagnosis of genetically proven familial AD;Groups 2 and 3:
- •- Current diagnosis of probable dementia of any etiology
- •- Current diagnosis of probable tauopathy of any etiology
研究者
相似试验
进行中（未招募）
1 期
The GLP-1 receptor agonist liraglutide can slow down the progression of Alzheimer’s diseaseMedDRA version: 14.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersAlzheimer's diseaseEUCTR2011-000794-31-DKDept. of Pharmacology
招募中
不适用
Study of neuroinflammation and aging of Alzheimer's dementia using multimodal neuroimaging (MRI and PET)KCT0005431Gachon University Gil Medical Center360
已完成
不适用
Immuneactivation in neurodegenerative diseasesUnspecified dementiaF00F03Dementia in Alzheimer diseaseDRKS00007914andesnervenklinik Wagner-Jauregg48
已完成
不适用
ongitudinal study across the spectrum of Alzheimer's disease associated with amyloid PET Imagings diseaseAlzheimer's diseaseJPRN-UMIN000014346Shonan-Atsugi hospital160
进行中（未招募）
不适用
Behaviour and cognition in Alzheimer s disease patients treated with the NMDA receptor antagonist memantine collelation with the apoptotic mechanisms.Treatment of patients with Alzheimer s DiseaseMedDRA version: 6.1Level: PTClassification code 10009843EUCTR2005-004498-31-ITFONDAZIONE SANTA LUCIA40